Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus

  • Rob N.M. Weijers , Dik J. Bekedam , Henk M.J. Goldschmidt and Yvo M. Smulders

Abstract

We examined the clinical usefulness of antepartum clinical characteristics, along with measures of glucose tolerance, in Dutch multiethnic women with gestational diabetes mellitus (GDM) for their ability to predict type 2 diabetes within 6months of delivery (early postpartum diabetes). The present study comprised a cross-sectional 5-year investigation (1998–2003) of a consecutive series of 168 women with GDM identified by a two-stage protocol at 16–33weeks of gestation. The following data were collected for all women: age and gestational age at entry into the study; prepregnancy body mass index (BMI); ethnicity; obstetric and clinical history, including the onset of early postpartum diabetes; pregnancy outcome; level of fasting C-peptide; and glycemic parameters of 50-g 1-h glucose challenge test and 100-g 3-h oral glucose tolerance test (diagnostic OGTT). We used receiver operating characteristic (ROC) curve analysis to test the clinical usefulness of the glycemic parameters. A total of 11 women (6.5%) developed early postpartum diabetes. Apart from family history of diabetes (p=0.052), anthropometric, maternal, and neonatal clinical parameters showed no association with early postpartum diabetes in univariate analyses. The level of fasting glucose, and both the glucose challenge test and diagnostic OGTT post-load glucose levels and glucose areas were associated with early postpartum diabetes. ROC curve analysis identifiedall three glucose challenge-test parameters, including fasting glucose concentration, as poor diagnostic tests, with a positive predictive value of ∼22%, whereas the positive predictive value associated with the area under the diagnostic OGTT curve increased progressively over monitoring time from 20.6% to 100%. Using a 3-h OGTT glucose area threshold of 35.7mmol·h/L resulted in 100% sensitivity and 100% specificity, identifying the 11 women who developed early postpartum diabetes. In summary, we can conclude from the present analysis that early postpartum diabetes is rare in GDM women (6.5%), and that the clinical usefulness of the total area under the diagnostic 3-h OGTT is superior to all other glycemic parameters for detecting early postpartum diabetes.


Corresponding author: R.N.M. Weijers, PhD, Department of Clinical Chemistry and Hematology, Onze Lieve Vrouwe Gasthuis, 1e Oosterparkstraat 279, P.O. Box 95500, Amsterdam 1090 HM, The Netherlands

References

1. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. Diabetes 1995; 44:586–91.10.2337/diab.44.5.586Search in Google Scholar

2. Schaefer-Graf UM, Buchanan TA, Xiang AH, Peters RK, Kjos SL. Clinical predictors for a high risk for the development of diabetes mellitus in the early puerperium in women with recent gestational diabetes mellitus. Am J Obstet Gynecol 2002; 186:751–6.10.1067/mob.2002.121895Search in Google Scholar

3. Kjos SL, Buchanan TA, Greenspoon JS, Montoro M, Bernstein GS, Mestman JH. Gestational diabetes mellitus: the prevalence of glucose intolerance and diabetes mellitusin the first two months post partum. Am J Obstet Gynecol 1990; 163:93–8.10.1016/S0002-9378(11)90676-0Search in Google Scholar

4. Buchanan TA, Xiang A, Kjos SL, Lee WP, Trigo E, Nader I, et al. Gestational diabetes: antepartum characteristics that predict postpartum glucose intolerance and type 2 diabetes in Latino women. Diabetes 1998; 47:1302–10.10.2337/diab.47.8.1302Search in Google Scholar

5. Metzger BE, Cho NH, Roston SM, Radvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. Diabetes Care 1993; 16:1598–605.10.2337/diacare.16.12.1598Search in Google Scholar

6. Damm P, Kuhl C, Bertelsen A, Molsted-Pedersen L. Predictive factors for the development of diabetes in women with previous gestational diabetes mellitus. Am J Obstet Gynecol 1992; 167:607–16.10.1016/S0002-9378(11)91559-2Search in Google Scholar

7. Cousins L, Baxi L, Chez R, Coustan D, Gabbe S, Harris J, et al. Screening recommendations for gestational diabetes mellitus. Am J Obstet Gynecol 1991; 165:493–6.10.1016/0002-9378(91)90273-TSearch in Google Scholar

8. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 1998; 21(Suppl 2):B161–7.Search in Google Scholar

9. Alberti KG, Skrabalo Z. Standardization of biochemical methods in the diagnosis and management of diabetes. IDF Bulletin 1982; 27:17–24.Search in Google Scholar

10. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of a WHO consultation. Geneva: World Health Organization, 1999.Search in Google Scholar

11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.10.2337/diacare.20.7.1183Search in Google Scholar PubMed

12. Weijers RN, Bekedam DJ, Smulders YM. Determinants of mild gestational hyperglycemia and gestational diabetes mellitus in a large Dutch multiethnic cohort. Diabetes Care 2002; 25:72–7.10.2337/diacare.25.1.72Search in Google Scholar PubMed

13. Guzick DS. Polycystic ovary syndrome. Obstet Gynecol 2004; 103:181–93.10.1097/01.AOG.0000104485.44999.C6Search in Google Scholar PubMed

14. Waldhäusl W, Bratusch-Marrain P, Gasic S, Korn A, Nowotny P. Schätzung der Insulinproduktion während oraler Glucosebelastung mittels Lebervenenkathedertechnik und Bestimmung von C-Peptid. In: Grüneklee D, Herzog W, editors. Die Bedeutung der C-Peptidbestimmung für die Diagnostik. Konstanz, Germany: Schnetztor Verlag, 1979:49–57.Search in Google Scholar

15. Treskes M, Adriaansen HJ, van der Leur SJ, Idema RN, Péquériaux N, Pronk C. Multicentre evaluation of the EBIO plus glucose analyser. Eur J Clin Chem Clin Biochem 1996; 34:777–84.Search in Google Scholar

16. Boyd JC. Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Lab Invest 1997; 57(Suppl 227):46–63.10.1080/00365519709168308Search in Google Scholar

17. Hanna FW, Peters JR. Screening for gestational diabetes; past, present and future. Diabet Med 2002; 19:351–8.10.1046/j.1464-5491.2002.00684.xSearch in Google Scholar

18. Yogev Y, Langer O, Xenakis EM, Rosenn B. Glucose screening in Mexican-American women. Obstet Gynecol 2004; 103:1241–5.10.1097/01.AOG.0000124781.98059.feSearch in Google Scholar

19. Campbell MJ, Machin D. Medical statistics. A commonsense approach. Chichester: John Wiley & Sons, 1993:7–31.10.2307/2532284Search in Google Scholar

20. Greenberg LR, Moore TR, Murphy H. Gestational diabetes: antenatal variables as predictors of postpartum glucose intolerance. Obstet Gynecol 1995; 86:97–101.10.1016/0029-7844(95)00103-XSearch in Google Scholar

21. Engelgau MM, Herman WH, Smith PJ, German RR, Aubert RE. The epidemiology of diabetes and pregnancy in the US, 1988. Diabetes Care 1995; 18:1029–33.10.2337/diacare.18.7.1029Search in Google Scholar PubMed

Received: 2005-8-18
Accepted: 2005-10-5
Published Online: 2011-9-21
Published in Print: 2006-1-1

©2006 by Walter de Gruyter Berlin New York

Downloaded on 4.5.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2006.019/html
Scroll to top button